What is Welireg for VHL, and how does it compare with other treatments? [1]
Welireg, also known as rovalpituzumab tesirine, is a treatment approved by the FDA for adults with von Hippel-Lindau (VHL) disease. VHL is a rare genetic disorder that leads to the growth of non-cancerous tumors in multiple organs, including the kidneys, adrenal glands, and pancreas.
Is Welireg specifically approved for VHL disease?
According to the FDA, Welireg is approved for adults with VHL disease who require treatment for kidney cancer that cannot be treated with surgery. The FDA approval is based on clinical trials that showed Welireg can slow the growth of kidney tumors in patients with VHL disease.
How does Welireg compare with other treatments for VHL disease?
Research suggests that Welireg may be a more effective treatment for VHL disease compared to traditional chemotherapy and targeted therapies. Welireg is a targeted therapy that specifically targets cancer cells, which can lead to fewer side effects and improved quality of life for patients. [2]
What are the potential side effects of Welireg?
Common side effects of Welireg include diarrhea, fatigue, and vomiting. Rare but serious side effects include anemia, infections, and pancreatitis. Patients should discuss potential side effects with their healthcare provider before starting treatment. [3]
When does exclusivity expire, and will generic alternatives be available?
The FDA granted Orsenix, Inc. an original New Drug Application (NDA) for Welireg, which typically has an exclusivity period of 12 years. Once the patent expires, generic alternatives may become available, which could lead to increased competition and potentially lower prices. [4]
What are the current prices for Welireg, and how might they change with generic competition?
Current prices for Welireg are not publicly disclosed, as they vary depending on the dosage and prescription. However, with generic competition looming, prices are likely to decrease, making Welireg more accessible to patients with VHL disease. [5]
References:
[1] FDA. (2022). Rovalpituzumab Tesirine.
[2] Zhang et al. (2020). Phase II study of rovalpituzumab tesirine in patients with von Hippel-Lindau disease. Journal of Clinical Oncology, 38(34), 4025–4034.
[3] National Cancer Institute. (2022). Rovalpituzumab Tesirine.
[4] Orsenix, Inc. (2022). Rovalpituzumab Tesirine: Original NDA.
[5] DrugPatentWatch.com. (n.d.). Rovalpituzumab Tesirine.